Procysbi (Cysteamine Bitartrate) Patent Expiration, LOE Window & CMS Spending
Procysbi (Cysteamine Bitartrate) by Amgen: FDA Orange Book core substance LOE 2027-07-26 (last listed 2037-02-16), 0 AB generics, $121.1M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Amgen |
| FDA Application & Pathway | N203389 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2027-07-26 |
| Last Listed Patent or Exclusivity Date | 2037-02-16 |
| Orange Book Patents (*PED Extensions) | 24 patents (12 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $121.1M |
| 2024 Medicare Part D Spend | $38.0M |
| 2024 Medicaid Spend | $83.1M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.